Varicella Zoster Virus gpII Antibody (SG2): sc-58074

Varicella Zoster Virus gpII Antibody (SG2) is a mouse monoclonal IgG1 antibody that detects Varicella Zoster Virus gpII protein through western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-Varicella Zoster Virus gpII antibody (SG2) is available as a non-conjugated format. The Varicella Zoster Virus, commonly known as VZV, causes childhood chickenpox (varicella) and shingles (zoster). Understanding Varicella Zoster Virus glycoprotein II structure is crucial, as this protein plays a vital role in host cell infection and immune response evasion. Glycoprotein II, a key viral envelope component, facilitates virus fusion with host cell membranes, enabling viral entry and replication. Multiple domains within glycoprotein II interact with host cell receptors to enhance viral infectivity. Glycoprotein II also participates in new virion assembly and release, making this protein a potential therapeutic target for controlling VZV infections. Varicella Zoster Virus gpII (SG2) monoclonal antibody enables researchers to study glycoprotein II function and interactions, advancing understanding of VZV pathogenesis and treatment approaches.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Varicella Zoster Virus gpII Antibody (SG2) References:

1. Transcription factor Sp1 is involved in the regulation of varicella-zoster virus glycoprotein E.  |  Rahaus, M. and Wolff, MH. 2000. Virus Res. 69: 69-81. PMID: 10989187
2. Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument.  |  Wang, ZH., et al. 2001. J Virol. 75: 323-40. PMID: 11119602
3. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates.  |  Kleinschmidt-DeMasters, BK. and Gilden, DH. 2001. Arch Pathol Lab Med. 125: 770-80. PMID: 11371229
4. Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I.  |  Kimura, H., et al. 1997. Virology. 233: 382-91. PMID: 9217061
5. Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.  |  Cohen, JI. and Nguyen, H. 1997. J Virol. 71: 6913-20. PMID: 9261418
6. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.  |  Mallory, S., et al. 1997. J Virol. 71: 8279-88. PMID: 9343180

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Varicella Zoster Virus gpII Antibody (SG2) has 1 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Varicella Zoster Virus gpII Antibody (SG2) Specifications

Alternate Product Name: Varicella Zoster Virus gpII

Product Clone Name: SG2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: Varicella Zoster Virus gpII

Epitope Species: Varicella Zoster virus, Ellen strain

Product Reactivity/Detection: the Varicella Zoster Virus glycoprotein II (VZVgB)

Species Reactivity/Detection: NSR

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for Varicella Zoster Virus gpII Antibody (SG2): N/A